Last reviewed · How we verify

NCT05298488

The Effect of Working at Home to Reduce Risk of Respiratory Infection

Status unknown NA Last updated 28 March 2022
What this trial tests

NA trial testing Home office in Respiratory Tract Infections in 2,000 participants. Status unknown.

Timeline
14 March 2022
Primary endpoint
30 March 2023
30 September 2023

Quick facts

Lead sponsorNorwegian Institute of Public Health
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeprevention
Enrollment2,000
Start date14 March 2022
Primary completion30 March 2023
Estimated completion30 September 2023
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Norwegian Institute of Public Health

Who can join

18 and older, any sex, with Respiratory Tract Infections or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The researchers will recruit volunteers from various organisations who are willing and able to be randomised to either working from home for 4 weeks followed by working in the office for 4 weeks, or vice versa. The goal is to assess whether working from home has an impact on the risk of symptoms of respiratory infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Respiratory Tract Infections

Currently open trials in the same condition.

Other Norwegian Institute of Public Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05298488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing